Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19717593 | 0.97 | HPGD (0.56) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL19633473 | 0.92 | HPGD (0.54) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL34473785 | 0.89 | USP30 (0.53) | EPHX1HPGDRECQLGPR119USP30 | |
| SCHEMBL12919349 | 0.88 | HPGD (0.50) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL24779359 | 0.88 | DDB1 (0.55) | EPHX1HPGDRECQLUSP2SMN1; SMN2 | |
| SCHEMBL2675028 | 0.85 | RECQL (0.52) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL23267860 | 0.85 | HPGD (0.48) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL2673967 | 0.85 | RECQL (0.59) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL4186514 | 0.84 | HPGD (0.57) | EPHX1HPGDRECQLGPR119USP2 | |
| SCHEMBL4186516 | 0.84 | HPGD (0.57) | EPHX1HPGDRECQLGPR119USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024020522-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216516-A1 | GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | EPHX1 2475/4885HPGD 607/4885RECQL 1296/4885 |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | EPHX1 1549/4885HPGD 1591/4885RECQL 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.